SCLXHealthcare · Drug Manufacturers - GeneralSCLX Stock Forecast: Scilex Holding Co. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 19 Sept 2026 — in the weakest quartile.
SCLX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Scilex Holding Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (85): Smaller than most of the companies we track.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
SCLX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SCLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Apr 2025 | D. Boral Capital | Downgrade | Hold | — |
| 2 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Jan 2025 | D. Boral Capital | Initiates | Buy | — |
| 21 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Oct 2024 | Alliance Global Partners | Initiates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 June 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 11 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Dec 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Oct 2023 | B. Riley Securities | Initiates | Buy | — |
| 9 Oct 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 Dec 2022 | GLJ Research | Downgrade | Sell | — |
| 28 Nov 2022 | JP Morgan | Downgrade | Neutral | — |
| 15 Nov 2022 | Deutsche Bank | Initiates | Buy | — |
| 7 Nov 2022 | Keybanc | Maintains | Overweight | — |
| 1 Nov 2022 | Barclays | Upgrade | Equal-Weight | — |
| 1 Nov 2022 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCLX appears on the weeks it earns a place.
SCLX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 21 Sept 2026, Scilex Holding Co. returned −71.5% against +17.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SCLX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Scilex Holding Co. (SCLX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- 1.1×
- Price / book
- −0.1×
- EV / EBITDA
- −0.5×
Cheaper than 77% of US stocks
Cheaper than 66% of US stocks
Cheaper than 93% of US stocks
Cheaper than 64% of US stocks
- Revenue growth (YoY)
- −22.8%
- Earnings growth (YoY)
- −22.8%
- Gross margin
- 51.9%
- Operating margin
- −385.0%
- Net margin
- 65.0%
Higher than 11% of US stocks
Higher than 19% of US stocks
Higher than 64% of US stocks
Higher than 8% of US stocks
Higher than 97% of US stocks
- Return on equity
- 190.1%
- Return on assets
- −105.8%
- Dividend yield
- —
Higher than 98% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Scilex Holding Co. (SCLX) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Scilex Holding Co. has a market value of $35.5M and an enterprise value of $138.7M.
Revenue in the twelve months to 30 June 2026: $31.6M. The latest quarter shrank 22.8% year on year.
Net income over the same four quarters: −$464.6M, a −1469.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$18.4M.
Trailing P/E: −0.1×; forward P/E: 6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Scilex Holding Co. employs 34 people — $930K of revenue per employee.
Data provided by Twelve Data
SCLX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| SCLXScilex Holding Co. | $35.5M | 13 |
| MIRAMIRA Pharmaceuticals, Inc. | $34.9M | 27 |
| NSRXNasus Pharma Ltd. | $41.3M | 17 |
| CCELCryo-Cell International, Inc.* | $35.5M | 77 |
| HBIOHarvard Bioscience, Inc.* | $35.6M | 98 |
| ATYRaTyr Pharma, Inc.* | $35.6M | 49 |
| DCGODocGo, Inc.* | $35.1M | 35 |
* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Scilex Holding Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about SCLX stock
Is SCLX stock a buy right now?
Of the 1 analysts covering Scilex Holding Co., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scilex Holding Co. 13 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SCLX?
As at 19 Sept 2026, Scilex Holding Co. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).
What is the SCLX stock forecast for 2030?
No analyst covering Scilex Holding Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCLX are extrapolating price history, which says nothing about the business.
How has SCLX stock performed over the past year?
Scilex Holding Co. returned -71.5% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Scilex Holding Co. do?
Scilex Holding Co. is a commercial biopharmaceutical company focused on developing and marketing non-opioid pain management products for acute and chronic pain.
About Scilex Holding Co.
Scilex Holding Co. is a commercial biopharmaceutical company focused on developing and marketing non-opioid pain management products for acute and chronic pain. Its current portfolio includes ZTlido, a topical lidocaine patch used for neuropathic pain linked to postherpetic neuralgia, ELYXYB, an oral solution for the acute treatment of migraine in adults, and GLOPERBA, a liquid oral colchicine product for gout flare prophylaxis. The company operates in the healthcare and pharmaceuticals market, serving the need for alternatives to opioid-based therapies through prescription products designed for targeted pain conditions. Scilex Holding Co. also works across product acquisition, development, and commercialization, giving it a role in both specialty pain treatment and broader pharmaceutical distribution. Based in Palo Alto, California, the company is positioned within the non-opioid pain management segment of the biopharmaceutical industry.
CEO Dr. Henry H. Ji Ph.D. · 34 employees · United States · https://www.scilexholding.com